Agenus News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

28.07.17	Gainers & Losers Of July 27: CAPR, ANIK, MMSI, AZN, TTPH, AGEN... (RTTNews)
27.07.17	Agenus to Report Second Quarter 2017 Financial Results on August 3, 2017; Conference Call to Follow (PR Newswire)
21.06.17	GSK presents positive results from Phase III revaccination study of its candidate shingles vaccine Shingrix at CDC's Advisory Meeting (PR Newswire)
21.06.17	Positive Phase 3 for GSK's shingles vaccine Shingrix with Agenus' QS-21 Stimulon® immune adjuvant (PR Newswire)
21.06.17	Agenus to Webcast Annual Meeting of Stockholders (PR Newswire)
13.06.17	Pharma and Biotech Companies Significantly Investing in R&D, Focus on Rising Demand for Advanced Medicines (PR Newswire)
13.06.17	Pharma and Biotech Companies Significantly Investing in R&D, Focus on Rising Demand for Advanced Medicines (PR Newswire)
05.06.17	Agenus' anti-CTLA-4 antibody shows strong safety and tolerability (PR Newswire)
01.06.17	Agenus to Participate at Two Upcoming Conferences in New York City: Jefferies Healthcare and JMP Securities Life Sciences (PR Newswire)
22.05.17	Agenus to present safety results for anti-CTLA-4 antibody at ASCO 2017 Annual Meeting (PR Newswire)
19.05.17	Research Reports Initiation on Biotech Stocks -- Agenus, Athersys, Actinium Pharma, and AVEO Pharma (PR Newswire)
04.05.17	Agenus Reports First Quarter 2017 Financial Results and Provides Corporate Update (PR Newswire)
27.04.17	Agenus to Report First Quarter 2017 Financial Results on May 4, 2017; Conference Call to Follow (PR Newswire)
20.04.17	Phase 1/2 Clinical Trial of Agenus' anti-PD-1 Antibody Begins (PR Newswire)
05.04.17	Agenus Commences Phase 1 Trial with Neoantigen Cancer Vaccine AutoSynVax™ (PR Newswire)
30.03.17	Agenus Restructures Business to Sharpen Focus on Clinical Development of Cancer Therapies (PR Newswire)
30.03.17	Research Reports Coverage on Biotech Stocks -- Agenus, Intrexon, Progenics Pharma, and Concordia (PR Newswire)
24.03.17	Agenus to Participate at Two Upcoming Immuno-Oncology Conferences (PR Newswire)
23.03.17	Innovative Immunotherapies Emerging as the Cancer Treatments of the Future (PR Newswire)
23.03.17	Innovative Immunotherapies Emerging as the Cancer Treatments of the Future (PR Newswire)
09.03.17	Agenus Reports Fourth Quarter and Full Year 2016 Results (PR Newswire)
07.03.17	Four Agenus Abstracts Accepted for Presentation at the American Association for Cancer Research (AACR) 2017 Annual Meeting (PR Newswire)
02.03.17	Agenus to Report Fourth Quarter and Year End 2016 Financial Results on March 9, 2017; Conference Call to Follow (PR Newswire)
27.02.17	New Cancer Therapeutics Drive the Cancer Biological Therapy Market (PR Newswire)
14.02.17	How These Biotech Stocks are Faring? -- Agenus, Tokai Pharma, Eleven Biotherapeutics, and Rexahn Pharma (PR Newswire)
30.01.17	Agenus Appoints Jean-Marie Cuillerot, M.D. Chief Medical Officer (PR Newswire)
17.01.17	Agenus announces collaboration with the National Cancer Institute to evaluate the combination of Pembrolizumab (Keytruda®, Merck & Co., Inc.) with Prophage™ (Agenus Inc.) autologous vaccine (PR Newswire)
15.12.16	How These Biotech Stocks are Faring? -- Agenus, Kite Pharma, Ocular Therapeutix, and Radius Health (PR Newswire)
30.11.16	Agenus Announces Commencement of Phase 1/2 Clinical Trial of anti-OX40 Checkpoint Antibody INCAGN1949 in Patients with Solid Tumors (PR Newswire)
24.07.15	GSK' Malaria Vaccine Containing Agenus'QS-21 Stimulon Gets Positive CHMP Opinion (RTTNews)
17.06.15	Agenus Appoints Evan Ballantyne As CFO (RTTNews)
24.04.15	Agenus : Final Study Results Show Significant Reduction In Malaria Cases (RTTNews)
09.01.15	Incyte, Agenus Report Alliance To Develop Novel Immuno-Oncology Antibodies (RTTNews)
18.12.14	Agenus: GSK's ZOE-50 Phase 3 Study Meets Primary Endpoint - Quick Facts (RTTNews)
01.07.14	Agenus : Brain Cancer Vaccine Shows Extended Survival In Phase 2 Study; Stock Up (RTTNews)
28.04.14	Agenus Signs Collaboration, License Agreement With Merck (RTTNews)
05.02.14	Agenus Prices Stock Offering (RTTNews)
14.01.14	Agenus Initiates Randomized Phase 2 Trial With Prophage For Melanoma (RTTNews)
16.12.13	Agenus Says Phase 2 Study Of Brain Cancer Vaccine Shows Improved Survival (RTTNews)
16.12.13	Agenus Announces Positive Phase 2 Data From Brain Cancer Vaccine Study (RTTNews)
07.11.13	Agenus: Genital Herpes Vaccine Meets Primary Endpoint In Phase 2 Trial (RTTNews)
11.10.13	Scheduled Earnings Releases, Survey and Study Results, and Enrollment into Clinical Trial - Research Report on Biogen Idec, Questcor, Medivation, Agenus, and Arrowhead Research (PR Newswire)
17.09.13	Agenus Reports Positive Phase 2 Results For Brain Cancer Vaccine (RTTNews)
21.09.09	Antigenics Announces Expansion of Its QS-21 License Agreement (Businesswire)
15.06.09	Tim Rothwell Joins Antigenics’ Board of Directors (Businesswire)
01.06.09	Antigenics Presents Positive Oncophage® Interim Survival Data at ASCO (Businesswire)
03.11.08	Antigenics to Present at the Rodman and Renshaw 10th Annual Healthcare Conference (Businesswire)
15.09.08	Antigenics to Present at the UBS 2008 Global Life Sciences Conference (Businesswire)
25.10.07	Aldi schliesst Alkohol-Webshop in Australien (Businesswire)
21.02.07	Antigenics Reports Fourth Quarter and Year-End 2006 Financial Results (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Logitech Intl	71.14	1.54 %	K V
UBS Group	28.08	1.48 %	K V
Swiss Re	130.05	1.05 %	K V
Part Grp Hldg	1’266.00	0.96 %	K V
ABB	49.48	0.94 %	K V
Geberit	525.20	0.27 %	K V
Alcon	78.04	0.05 %	K V
Givaudan	3’868.00	-0.31 %	K V
CieFinRichemont	121.20	-0.57 %	K V
Sonova Hldg	301.00	-0.99 %	K V

mehr

10.04.24		Mittwochshandel in New York: NASDAQ Composite liegt zum Ende des Mittwochshandels im Minus
10.04.24		Mittwochshandel in New York: NASDAQ Composite fällt mittags zurück
09.04.24		Pluszeichen in New York: NASDAQ Composite verbucht zum Handelsstart Zuschläge
08.04.24		Börse New York in Grün: NASDAQ Composite verbucht zum Handelsende Zuschläge
08.04.24		Starker Wochentag in New York: Am Nachmittag Gewinne im NASDAQ Composite
08.04.24		Freundlicher Handel in New York: NASDAQ Composite am Montagmittag mit Gewinnen
08.04.24		Börse New York: NASDAQ Composite steigt zum Start
05.04.24		Freitagshandel in New York: NASDAQ Composite beginnt Handel in der Gewinnzone

10.04.24

Mittwochshandel in New York: NASDAQ Composite liegt zum Ende des Mittwochshandels im Minus

10.04.24

Mittwochshandel in New York: NASDAQ Composite fällt mittags zurück

09.04.24

Pluszeichen in New York: NASDAQ Composite verbucht zum Handelsstart Zuschläge

08.04.24

Börse New York in Grün: NASDAQ Composite verbucht zum Handelsende Zuschläge

08.04.24

Starker Wochentag in New York: Am Nachmittag Gewinne im NASDAQ Composite

08.04.24

Freundlicher Handel in New York: NASDAQ Composite am Montagmittag mit Gewinnen